Brigitte C Widemann

Brigitte C Widemann

UNVERIFIED PROFILE

Are you Brigitte C Widemann?   Register this Author

Register author
Brigitte C Widemann

Brigitte C Widemann

Publications by authors named "Brigitte C Widemann"

Are you Brigitte C Widemann?   Register this Author

100Publications

2797Reads

13Profile Views

Severe Hepatotoxicity of Mithramycin Therapy Caused by Altered Expression of Hepatocellular Bile Transporters.

Mol Pharmacol 2019 Aug 7;96(2):158-167. Epub 2019 Jun 7.

Clinical Pharmacology Program (T.M.S., C.J.P., W.D.F.), Molecular Pharmacology Section (P.A.H., R.J.H., E.M.M., R.H.B., J.D.S., A.M.L., W.D.F.), Biostatistics and Data Management Section (M.Z., J.A.H., D.V.), Pediatric Oncology Branch (P.G., J.G., B.C.W.), Thoracic Surgery Branch, Center for Cancer Research, National Cancer Institute (D.S.S.), and Translational Hepatology Section (T.H.), Liver Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, Maryland; and BioIVT, ADME-Tox Division, Durham, North Carolina (J.P.J., K.R.B.)

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1124/mol.118.114827DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6608607PMC
August 2019

Improved CNS exposure to tocilizumab after cerebrospinal fluid compared to intravenous administration in rhesus macaques.

Blood 2018 08 28;132(6):662-666. Epub 2018 Jun 28.

Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD; and.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood-2018-05-846428DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6086204PMC
August 2018

Creating a comprehensive research strategy for cutaneous neurofibromas.

Neurology 2018 07;91(2 Suppl 1):S1-S4

From the Department of Neurology (J.O.B., R.J., M.S., S.K.V.), The Johns Hopkins School of Medicine, The Neurofibromatosis Therapeutic Acceleration Program, Baltimore, MD; Department of Dermatology (P.W.), Paris Est Créteil University, France; Pediatric Oncology Branch (B.C.W.), National Cancer Institute, NIH, Bethesda, MD; Dermavant Sciences (J.L.), Durham, NC; and Department of Dermatology (L.Q.L.), UT Southwestern Medical Center, Dallas, TX.

View Article

Download full-text PDF

Source
http://www.neurology.org/lookup/doi/10.1212/WNL.000000000000
Publisher Site
http://dx.doi.org/10.1212/WNL.0000000000005789DOI Listing
July 2018

Clinical trial design for cutaneous neurofibromas.

Neurology 2018 07;91(2 Suppl 1):S31-S37

From the Department of Genetics (A.C., B.K.), University of Alabama at Birmingham; BioPharm Tech (K.J.), San Mateo, CA; Pediatric Oncology Branch (B.C.W.) and Dermatology Branch, Center for Cancer Research (D.C.P.), National Cancer Institute, NIH, Bethesda; Division of Oncology Products (D.C.) and Division of Dermatology and Dental Products (H.-S.K.), Food and Drug Administration, Silver Spring; and Department of Neurology (J.O.B., S.K.V.), The Neurofibromatosis Therapeutic Acceleration Program, The Johns Hopkins University School of Medicine, Baltimore, MD.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1212/WNL.0000000000005790DOI Listing
July 2018

Identifying Symptoms of Distress in Youth Living with Neurofibromatosis Type 1 (NF1).

J Genet Couns 2018 02 23;27(1):115-123. Epub 2017 Jul 23.

National Institute of Mental Health, Office of the Clinical Director, Bethesda, MD, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10897-017-0128-1DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6287491PMC
February 2018

Volumetric MRI Analysis of Plexiform Neurofibromas in Neurofibromatosis Type 1: Comparison of Two Methods.

Acad Radiol 2018 02 31;25(2):144-152. Epub 2017 Oct 31.

Center for Cancer Research, Pediatric Oncology Branch, National Cancer Institute, 10 Center Drive, CRC Room 1-5750, Bethesda, MD 20892. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.acra.2017.09.004DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5794522PMC
February 2018

Biology and Management of Undifferentiated Pleomorphic Sarcoma, Myxofibrosarcoma, and Malignant Peripheral Nerve Sheath Tumors: State of the Art and Perspectives.

J Clin Oncol 2018 01 8;36(2):160-167. Epub 2017 Dec 8.

Brigitte C. Widemann, National Cancer Institute, Bethesda, MD; and Antoine Italiano, Institut Bergonié and University of Bordeaux, Bordeaux, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2017.75.3467DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5759316PMC
January 2018

Editorial: US Cancer Statistics of Survival: Achievements, Challenges, and Future Directions.

J Natl Cancer Inst 2017 09;109(9)

Clinical Genetics Branch, Division of Cancer Epidemiology and Genetics, and Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/jnci/djx070DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6059201PMC
September 2017

Neurofibromatosis Type 1-Associated MPNST State of the Science: Outlining a Research Agenda for the Future.

J Natl Cancer Inst 2017 08;109(8)

Rare Tumor Initiative, Laboratory of Pathology, and Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD; Center for Cancer and Blood Disorders, Children's National Medical Center, Washington, DC; Department of Neurology, Johns Hopkins Hospital, Baltimore, MD; Neurofibromatosis Center, Department of Neurology Guy's Hospital London, London, UK; Department of Neurology, Washington University School of Medicine, St. Louis, MO; Department of Human Genetics, University of Leuven, Leuven, Belgium; Hunstman Cancer Institute, University of Utah, Salt Lake City, UT; Division of Experimental Hematology and Cancer Biology, Department of Pediatrics, Cincinnati Children's Hospital, University of Cincinnati, Cincinnati, OH; Bill and Melinda Gates Foundation, Seattle, WA; Children's Tumor Foundation, New York, NY; Clinical Genetics Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, MD.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/jnci/djx124DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6057517PMC
August 2017

Malignant Peripheral Nerve Sheath Tumors State of the Science: Leveraging Clinical and Biological Insights into Effective Therapies.

Sarcoma 2017 16;2017:7429697. Epub 2017 May 16.

National Cancer Institute, Pediatric Oncology Branch, 10 Center Drive, Room 1-3742, Building 10, Bethesda, MD 20892, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1155/2017/7429697DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5448069PMC
May 2017

Validity, specificity, feasibility and acceptability of a brief pediatric distress thermometer in outpatient clinics.

Psychooncology 2017 04 30;26(4):461-468. Epub 2015 Nov 30.

National Institute of Mental Health, Bethesda, MD, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/pon.4038DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4969217PMC
April 2017

Selumetinib in Plexiform Neurofibromas.

N Engl J Med 2017 03;376(12):1195

National Cancer Institute, Bethesda, MD.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMc1701029DOI Listing
March 2017

Activity of Selumetinib in Neurofibromatosis Type 1-Related Plexiform Neurofibromas.

N Engl J Med 2016 12;375(26):2550-2560

From the Center for Cancer Research, Pediatric Oncology Branch, Bethesda (E.D., A. Baldwin, L.J.M., P. Whitcomb, S.M., R.E., P. Wolters, J.T., J.G., A.J.S., A.G., B.C.W.) and the Cancer Therapy Evaluation Program, Shady Grove (A.L.D.), National Cancer Institute, and the National Heart, Lung, and Blood Institute (A. Brofferio), Bethesda, National Institutes of Health, and the Food and Drug Administration, Silver Spring (L.J.M., R.E.) - all in Maryland; the Division of Oncology, Children's Hospital of Philadelphia, and the Department of Pediatrics, Perelman School of Medicine at the University of Pennsylvania, Philadelphia (M.J.F., J.B.B.); Children's National Health System, Washington, DC (A.K.); and Cincinnati Children's Hospital, Cincinnati (B.W., L.E.A.-S., T.A.R., J.W., E.S., N.R.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1605943DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5508592PMC
December 2016

Outcome of Patients With Recurrent Osteosarcoma Enrolled in Seven Phase II Trials Through Children's Cancer Group, Pediatric Oncology Group, and Children's Oncology Group: Learning From the Past to Move Forward.

J Clin Oncol 2016 09 11;34(25):3031-8. Epub 2016 Jul 11.

Joanne P. Lagmay, Shands Hospital for Children, University of Florida, Gainesville, FL; Mark D. Krailo and Ha Dang, University of Southern California, Los Angeles; and Children's Oncology Group, Monrovia; Theodore Zwerdling, Jonathan Jaques Children's Cancer Center, Miller Children's and Women's Hospital, Long Beach, CA; AeRang Kim, Center for Cancer and Blood Disorders, Children's National Medical Center, Washington, DC; Douglas S. Hawkins, Seattle Children's Hospital, Fred Hutchinson Cancer Research Center, University of Washington, Seattle, WA; Orren Beaty III, Zeiss Children's Cancer Center, Mission Hospitals, Asheville, NC; Brigitte C. Widemann, National Institutes of Health Clinical Center, Bethesda, MD; Lisa Bomgaars and Susan M. Blaney, Baylor College of Medicine/Texas Children's Cancer Center, Houston; Anne-Marie Langevin, University of Texas Health Science Center at San Antonio, San Antonio, TX; Holcombe E. Grier and Katherine A. Janeway, Dana-Farber Cancer Institute, Boston Children's Cancer and Blood Disorders Center, Boston, MA; Brenda Weigel, University of Minnesota, Minneapolis, MN; and Richard Gorlick, The Albert Einstein College of Medicine of Yeshiva University, The Children's Hospital at Montefiore, New York, NY.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2015.65.5381DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5012712PMC
September 2016

Sleep and pulmonary outcomes for clinical trials of airway plexiform neurofibromas in NF1.

Neurology 2016 Aug;87(7 Suppl 1):S13-20

From the Neurology Department and Cancer Center (S.R.P.), Massachusetts General Hospital, Boston; Section of Pediatric Pulmonology, Allergy and Sleep Medicine (S.D.D.), and Stem Cell Transplantation Program (K.A.R.), Riley Children's Hospital, Indiana University School of Medicine, Indianapolis; Pediatric Oncology Branch (S.A., B.C.W.), National Cancer Institute, Bethesda, MD; Division of Pulmonary Medicine (J.A.), Division of Oncology (M.J.F.), and Sleep Center (C.L.M.), Children's Hospital of Philadelphia; Department of Pediatrics (M.J.F.) and Sleep Center (C.L.M.), The Perelman School of Medicine at the University of Pennsylvania (J.A.), Philadelphia; Department of Neurology (J.O.B.), John Hopkins Medical Institute, Baltimore, MD; and Department of Neurology (R.E.F.), Guy's and St. Thomas' NHS Foundation Trust and Institute of Psychiatry, King's College London, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1212/WNL.0000000000002933DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5578358PMC
August 2016

Current status and recommendations for biomarkers and biobanking in neurofibromatosis.

Neurology 2016 Aug;87(7 Suppl 1):S40-8

From Plymouth University (C.O.H.), Peninsula Schools of Medicine and Dentistry, The Institute of Translational and Stratified Medicine, Plymouth, UK; Department of Neurology (J.O.B.), Johns Hopkins University Medical School, Baltimore, MD; Department of Pediatrics (F.P.N.) and Department of Pediatrics, School of Medicine (K.R., M.F.), Indiana University; Tailored Therapeutics (F.P.N.), Eli Lilly and Company, Indianapolis, IN; Department of Pathology (A.S.-R.), Neuro-oncology (S.R.P.), Massachusetts General Hospital, Boston; Neurologische Klinik (V.M.), Uniklinik Eppendorf, Hamburg; Berlin-Brandenburg Center for Regenerative Therapies (A.K.), Charité Universitätsmedizin Berlin, Germany; Seoul National University (A.K.), College of Veterinary Medicine and Research Institute for Veterinary Science, Republic of Korea; NCI (B.C.W.), Pediatric Oncology Branch, Bethesda, MD; Genomic Medicine (D.G.E.), University of Manchester, UK; National Neurofibromatosis Service (R.F.), Department of Neurology, Guy's and St. Thomas' NHS Foundation Trust, London UK; Department of Pathology and Laboratory Medicine (S.L.C.), Medical University of South Carolina, Charleston; and Heflin Center for Genomic Sciences (B.K.), University of Alabama at Birmingham; Dermatology (P.W.), GHU Henri Mondor, Paris, France; Children's Tumor Foundation (P.K.), New York.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1212/WNL.0000000000002932DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5578360PMC
August 2016

Vincristine Sulfate Liposomes Injection (VSLI, Marqibo®): Results From a Phase I Study in Children, Adolescents, and Young Adults With Refractory Solid Tumors or Leukemias.

Pediatr Blood Cancer 2016 Jun 17;63(6):997-1005. Epub 2016 Feb 17.

Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health (NIH), Bethesda, Maryland;

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/pbc.25937DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6689398PMC
June 2016

Efficacy and Biomarker Study of Bevacizumab for Hearing Loss Resulting From Neurofibromatosis Type 2-Associated Vestibular Schwannomas.

J Clin Oncol 2016 05 14;34(14):1669-75. Epub 2016 Mar 14.

Jaishri O. Blakeley, Xiaobu Ye, Amanda L. Bergner, Laura M. Fayad, Shivani Ahlawat, and Michael A. Jacobs, Johns Hopkins University, Baltimore; Christopher Zalewski, National Institute on Deafness and Other Communication Disorders; Eva Dombi and Brigitte C. Widemann, National Cancer Institute, Bethesda, MD; Dan G. Duda, Alona Muzikansky, Vanessa L. Merker, Elizabeth R. Gerstner, Rakesh K. Jain, and Scott R. Plotkin, Massachusetts General Hospital; and Chris F. Halpin, Massachusetts Eye and Ear Infirmary, Boston, MA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2015.64.3817DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4872317PMC
May 2016

Reply to: Glucarpidase for the Treatment of Methotrexate-Induced Renal Dysfunction and Delayed Methotrexate Excretion.

Pediatr Blood Cancer 2016 Feb 21;63(2):366. Epub 2015 Oct 21.

Pharmacology and Experimental Therapeutics Section, Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/pbc.25798DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6675564PMC
February 2016

Plasma and cerebrospinal fluid pharmacokinetics of vincristine and vincristine sulfate liposomes injection (VSLI, marqibo®) after intravenous administration in Non-human primates.

Invest New Drugs 2016 Feb 10;34(1):61-5. Epub 2015 Dec 10.

Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Building 10, Room 1W-3750, 9000, Rockville Pike, Bethesda, MD, 20892-1104, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10637-015-0311-xDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6343835PMC
February 2016

Population pharmacokinetics of sirolimus in pediatric patients with neurofibromatosis type 1-Erratum.

Ther Drug Monit 2016 01 21. Epub 2016 Jan 21.

1Division of Pharmacy, Cincinnati Children's Hospital Medical Center 2Division of Clinical Pharmacology, Cincinnati Children's Hospital Medical Center 3Department of Pediatrics, University of Cincinnati, College of Medicine 4Cancer & Blood Disease Institute, Division of Oncology, Cincinnati Children's Hospital Medical Center 5Pediatric Oncology Branch, National Cancer Institute, Bethesda, MD 6Division of Oncology, The Children's Hospital of Philadelphia, Philadelphia, PA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/FTD.0000000000000275DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4956590PMC
January 2016

Pharmacokinetic and pharmacodynamic study of tariquidar (XR9576), a P-glycoprotein inhibitor, in combination with doxorubicin, vinorelbine, or docetaxel in children and adolescents with refractory solid tumors.

Cancer Chemother Pharmacol 2015 Dec 20;76(6):1273-83. Epub 2015 Oct 20.

The Children's Hospital of Philadelphia, The Perelman School of Medicine at The University of Pennsylvania, CTRB 4016, 3501 Civic Center Blvd, Philadelphia, PA, 19104, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00280-015-2845-1DOI Listing
December 2015

Cephalometry in adults and children with neurofibromatosis type 1: Implications for the pathogenesis of sphenoid wing dysplasia and the "NF1 facies".

Eur J Med Genet 2015 Nov 8;58(11):584-90. Epub 2015 Sep 8.

Clinical Genetics Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Rockville, MD, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejmg.2015.09.001DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4659762PMC
November 2015

Practical considerations for the administration of glucarpidase in high-dose methotrexate (HDMTX) induced renal dysfunction.

Pediatr Blood Cancer 2015 Sep 4;62(9):1512-3. Epub 2015 May 4.

Pharmacology and Experimental Therapeutics Section, Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/pbc.25577DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6626666PMC
September 2015

Age-dependent changes in sirolimus metabolite formation in patients with neurofibromatosis type 1.

Ther Drug Monit 2015 Jun;37(3):395-9

*Division of Clinical Pharmacology, Cincinnati Children's Hospital Medical Center; †Department of Pediatrics, College of Medicine, University of Cincinnati, OH; ‡iC42 Integrated Solutions in Clinical Research and Development, University of Colorado, Aurora; §Pediatric Oncology Branch, National Cancer Institute, Bethesda, MD; ¶Division of Oncology, The Children's Hospital of Philadelphia; ‖Department of Pediatrics, The Perelman School of Medicine, University of Pennsylvania, Philadelphia; **Division of Oncology, Cancer and Blood Disease Institute, Cincinnati Children's Hospital Medical Center; and ††Department of Pharmacology and Cell Biophysics, College of Medicine, University of Cincinnati, OH.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/FTD.0000000000000130DOI Listing
June 2015

Plasma and cerebrospinal fluid pharmacokinetics of the Akt inhibitor, perifosine, in a non-human primate model.

Cancer Chemother Pharmacol 2015 May 5;75(5):923-8. Epub 2015 Mar 5.

Pharmacology and Experimental Therapeutics, POB, NCI, NIH, Bethesda, MD, 20892, USA.

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s00280-015-2711-1
Publisher Site
http://dx.doi.org/10.1007/s00280-015-2711-1DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6301001PMC
May 2015

Sirolimus for progressive neurofibromatosis type 1-associated plexiform neurofibromas: a neurofibromatosis Clinical Trials Consortium phase II study.

Neuro Oncol 2015 Apr 14;17(4):596-603. Epub 2014 Oct 14.

Division of Oncology, Cincinnati Children's Hospital Medical Center, Cancer and Blood Diseases Institute, Cincinnati, Ohio (B.W., J.P.); Division of Genetics, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio (E.S.); Division of Clinical Pharmacology, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio (A.V.); National Cancer Institute, Pediatric Oncology Branch, Bethesda, Maryland (B.C.W, E.D., P.W.); Department of Genetics, University of Alabama at Birmingham, Birmingham, Alabama (B.K.); Department of Preventitive Medicine, University of Alabama at Birmingham, Birmingham, Alabama (A.C.); Department of Neurology, Boston Children's Hospital, Boston, Massachusetts (N.U.); Department of Neurology, Washington University, St. Louis, Missouri (D.H.G.); Children's National Health System, Center for Neuroscience and Behavioral Medicine, Washington, DC (R.J.P.); Division of Oncology, The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania (M.J.F.); Division of Genetics, Primary Children's Hospital, Salt Lake City, Utah (D.V.); Division of Neurology, The University of Chicago Medicine Comer Children's Hospital, Chicago, Illinois (J.T.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/neuonc/nou235DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4483073PMC
April 2015

Phase II/III trial of a pre-transplant farnesyl transferase inhibitor in juvenile myelomonocytic leukemia: a report from the Children's Oncology Group.

Pediatr Blood Cancer 2015 Apr 8;62(4):629-36. Epub 2014 Dec 8.

Department of Pediatrics, Helen Diller Comprehensive Cancer Center, University of California San Francisco School of Medicine and Benioff Children's Hospital, San Francisco, California.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/pbc.25342DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4339233PMC
April 2015

Characterization of spinal findings in children and adults with neurofibromatosis type 1 enrolled in a natural history study using magnetic resonance imaging.

J Neurooncol 2015 Jan 8;121(1):209-15. Epub 2014 Oct 8.

Department of Oncology, St. Jude Children's Research Hospital, 262 Danny Thomas Place, Memphis, TN, 38105, USA,

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11060-014-1629-5DOI Listing
January 2015

Radiation therapy in management of sporadic and neurofibromatosis type 1-associated malignant peripheral nerve sheath tumors.

Front Oncol 2014 17;4:324. Epub 2014 Nov 17.

Radiation Oncology Branch, National Cancer Institute, National Institutes of Health , Bethesda, MD , USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3389/fonc.2014.00324DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4233912PMC
December 2014

Genetic modifiers of neurofibromatosis type 1-associated café-au-lait macule count identified using multi-platform analysis.

PLoS Genet 2014 Oct 16;10(10):e1004575. Epub 2014 Oct 16.

Clinical Genetics Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Rockville, Maryland, United States of America.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1371/journal.pgen.1004575DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4199479PMC
October 2014

Phase 2 randomized, flexible crossover, double-blinded, placebo-controlled trial of the farnesyltransferase inhibitor tipifarnib in children and young adults with neurofibromatosis type 1 and progressive plexiform neurofibromas.

Neuro Oncol 2014 May 4;16(5):707-18. Epub 2014 Feb 4.

Pediatric Oncology Branch, National Cancer Institute, Bethesda, Maryland (B.W., E.D., A.G., P.W., S.M., E.F., F.B.); Cancer Therapy Evaluation Program, Investigational Drug Branch, National Cancer Institute, Bethesda, Maryland (J.W.); Biostatistics and Data Management Section, National Cancer Institute, Bethesda, Maryland (S.S.); Diagnostic Radiology Department, National Institutes of Health, Bethesda, Maryland (N.P.); The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania (J.B., E.F., F.B.); Ann and Robert H. Lurie Children's Hospital, Chicago, Illinois (S.G.); Department of Genetics, University of Alabama at Birmingham, South Birmingham, Alabama (B.K.); Expert Image Analysis LC, Potomac, Maryland (J.S.); Dana-Farber/Children's Hospital Cancer Center, Boston, Massachusetts (M.K.); Cincinnati Children's Hospital, Cincinnati, Ohio (J.P.); Children's National Medical Center, Washington, DC (A.K.); US Army Medical Research and Material Command, Fort Detrick, Maryland (W.S.); Children's Hospital of Alabama, Birmingham, Alabama (A.R.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/neuonc/nou004DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3984559PMC
May 2014

Puberty and plexiform neurofibroma tumor growth in patients with neurofibromatosis type I.

J Pediatr 2014 Mar 8;164(3):620-4. Epub 2013 Dec 8.

Pharmacology and Experimental Therapeutics Section, Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jpeds.2013.10.081DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3943976PMC
March 2014

PET-guided biopsy with needle navigation facilitates diagnosis of angiosarcoma in neurofibromatosis type 1.

Pediatr Blood Cancer 2013 Dec 7;60(12):E166-9. Epub 2013 Aug 7.

Center for Interventional Oncology, National Institutes of Health, Bethesda, Maryland; Radiology and Imaging Sciences, National Institutes of Health, Bethesda, Maryland; Duke University School of Medicine, Durham, North Carolina.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/pbc.24668DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3798049PMC
December 2013

Achieving consensus for clinical trials: the REiNS International Collaboration.

Neurology 2013 Nov;81(21 Suppl 1):S1-5

From the Neurology Department and Cancer Center (S.R.P.), Massachusetts General Hospital, Boston, MA; Department of Neurology, Neurosurgery, and Oncology (J.O.B.), Johns Hopkins, Baltimore, MD; Pediatric Oncology Branch (E.D., P.L.W., B.C.W.), National Cancer Institute, Bethesda, MD; Division of Oncology, Department of Pediatrics (M.J.F.), The Children's Hospital of Pennsylvania, Philadelphia; Plymouth University Peninsula Schools of Medicine and Dentistry (C.O.H.), Plymouth, United Kingdom; and The Jennifer and Daniel Gilbert Neurofibromatosis Institute (K.S.W.), Children's National Medical Center, Washington, DC.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1212/01.wnl.0000435743.49414.b6DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3908338PMC
November 2013

Recommendations for imaging tumor response in neurofibromatosis clinical trials.

Neurology 2013 Nov;81(21 Suppl 1):S33-40

From the Pediatric Oncology Branch (E.D., B.C.W.), National Cancer Institute, Bethesda, MD; Department of Neurology (S.L.A.-H.), The Children's Hospital at Westmead, Sydney, Australia; Department of Medical Genetics (D. B.-V.), Mayo Clinic, Rochester, MN; Neurosurgical Service (F.G.B.), Department of Radiology (G.J.H.), and Department of Neurology and Cancer Center (S.R.P.), Massachusetts General Hospital, Boston, MA; Department of Neuroradiology (S.C.), King's College Hospital, London, UK; Department of Genetic Medicine (D.G.E.), MAHSC, St Mary's Hospital, Manchester, UK; Division of Oncology (M.J.F.) and Department of Radiology (D.J.), The Children's Hospital of Philadelphia; Department of Pediatrics (M.J.F.), The Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA; Department of Neurosurgery (S.G.), Hôpital Beaujon, Clichy, France; Division of Pediatric Hematology/Oncology and NYU Cancer Institute (M.A.K.), NYU Langone Medical Center, New York, NY; Department of Genetics (B.R.K.), University of Alabama at Birmingham, Birmingham, AL; Department of Neurology (V.M.), University Medical Center Hamburg-Eppendorf, Hamburg, Germany; Department of Radiology (T.Y.P.), Boston Children's Hospital, Boston, MA; and Department of Pediatrics (K.R., C.-S.S.), Riley Hospital for Children, Indianapolis, IN.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1212/01.wnl.0000435744.57038.afDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3908340PMC
November 2013

Conclusions and future directions for the REiNS International Collaboration.

Neurology 2013 Nov;81(21 Suppl 1):S41-4

From the Pediatric Oncology Branch (B.C.W., E.D., P.L.W.), National Cancer Institute, Bethesda, MD; Department of Neurology, Neurosurgery, and Oncology (J.O.B.), Johns Hopkins, Baltimore, MD; Division of Oncology, Department of Pediatrics (M.J.F.), The Children's Hospital of Pennsylvania, Philadelphia; Plymouth University Peninsula Schools of Medicine and Dentistry (C.O.H.), Plymouth, United Kingdom; The Jennifer and Daniel Gilbert Neurofibromatosis Institute (K.S.W.), Children's National Medical Center, Washington, DC; and Neurology Department and Cancer Center (S.R.P.). Massachusetts General Hospital, Boston, MA.

View Article

Download full-text PDF

Source
http://www.neurology.org/content/81/21_supplement_1/S41.full
Web Search
http://www.neurology.org/cgi/doi/10.1212/01.wnl.0000435748.7
Publisher Site
http://dx.doi.org/10.1212/01.wnl.0000435748.79908.c5DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3908339PMC
November 2013

Visual outcomes in children with neurofibromatosis type 1 and orbitotemporal plexiform neurofibromas.

Am J Ophthalmol 2013 Jun 26;155(6):1089-1094.e1. Epub 2013 Feb 26.

Department of Neurology, Children's National Medical Center, Washington, DC, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ajo.2013.01.011DOI Listing
June 2013

Using a lower dose of glucarpidase to reduce plasma levels of methotrexate.

Clin Adv Hematol Oncol 2013 May;11(5):324-5

Pediatric Oncology Branch, National Cancer Institute, Bethesda, MD 20892, USA.

View Article

Download full-text PDF

Source
May 2013

Bone mineral density in children and young adults with neurofibromatosis type 1.

Endocr Relat Cancer 2012 Dec 19;19(6):817-25. Epub 2012 Nov 19.

Section on Endocrinology and Genetics, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, Maryland 20892, USA.

View Article

Download full-text PDF

Source
https://erc.bioscientifica.com/view/journals/erc/19/6/817.xm
Publisher Site
http://dx.doi.org/10.1530/ERC-12-0293DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4132947PMC
December 2012

Phase I trial and pharmacokinetic study of lexatumumab in pediatric patients with solid tumors.

J Clin Oncol 2012 Nov 15;30(33):4141-7. Epub 2012 Oct 15.

National Cancer Institute, National Institutes of Health, 10 Center Dr, Building 10 CRC, Room 1W-3750, Bethesda, MD 20892-1104, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2012.44.1055DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3494837PMC
November 2012

The plasma and cerebrospinal fluid pharmacokinetics of sorafenib after intravenous administration in non-human primates.

Invest New Drugs 2012 Apr 12;30(2):524-8. Epub 2010 Nov 12.

Pediatric Oncology Branch, Pharmacology and Experimental Therapeutics Section, National Cancer Institute, 10 Center Drive, Building 10-CRC, Bethesda, MD 20892, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10637-010-9585-1DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6636925PMC
April 2012

Preclincial testing of sorafenib and RAD001 in the Nf(flox/flox) ;DhhCre mouse model of plexiform neurofibroma using magnetic resonance imaging.

Pediatr Blood Cancer 2012 Feb 11;58(2):173-80. Epub 2011 Feb 11.

Cincinnati Children's Hospital Research Foundation, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/pbc.23015DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3128176PMC
February 2012

The plasma and cerebrospinal fluid pharmacokinetics of the platinum analog satraplatin after intravenous administration in non-human primates.

Cancer Chemother Pharmacol 2012 Jan 26;69(1):247-52. Epub 2011 Jun 26.

National Cancer Institute, Pediatric Oncology Branch, 10 Center Drive, Building 10-CRC, Room 1-5742, Bethesda, MD 20892-1101, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00280-011-1659-zDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6300136PMC
January 2012

Plasma and CNS pharmacokinetics of O4-benzylfolic acid (O4BF) and metabolite in a non-human primate model.

Cancer Chemother Pharmacol 2011 Jun 20;67(6):1291-7. Epub 2010 Aug 20.

Pediatric Oncology Branch, National Cancer Institute, 10 Center Drive, Building 10/Rm 1W-5750, Bethesda, MD 20892, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00280-010-1407-9DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6675565PMC
June 2011

Pediatric phase I trial design using maximum target inhibition as the primary endpoint.

J Natl Cancer Inst 2010 Jun 11;102(12):909-12. Epub 2010 May 11.

Department of Hematology/Oncology, Children's National Medical Center, 111 Michigan Ave NW, Washington, DC 20010, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/jnci/djq174DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2886096PMC
June 2010

Sorafenib and sunitinib.

Oncologist 2009 Aug 1;14(8):800-5. Epub 2009 Aug 1.

Pediatric Oncology Branch, National Cancer Institute, Bethesda, Maryland 20892, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1634/theoncologist.2009-0088DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6626665PMC
August 2009

Current status of sporadic and neurofibromatosis type 1-associated malignant peripheral nerve sheath tumors.

Curr Oncol Rep 2009 Jul;11(4):322-8

Pediatric Oncology Branch, National Cancer Institute, 10 Center Drive, Bethesda, MD 20892, USA.

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6689400PMC
http://dx.doi.org/10.1007/s11912-009-0045-zDOI Listing
July 2009

Phase I trial and pharmacokinetic study of ixabepilone administered daily for 5 days in children and adolescents with refractory solid tumors.

J Clin Oncol 2009 Feb 15;27(4):550-6. Epub 2008 Dec 15.

Pediatric and Medical Oncology Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD 20892, USA.

View Article

Download full-text PDF

Source
http://ascopubs.org/doi/10.1200/JCO.2008.17.6644
Publisher Site
http://dx.doi.org/10.1200/JCO.2008.17.6644DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2645861PMC
February 2009

Assessment of benign tumor burden by whole-body MRI in patients with neurofibromatosis 1.

Neuro Oncol 2008 Aug 17;10(4):593-8. Epub 2008 Jun 17.

Department of Maxillofacial Surgery, University Hospital Eppendorf, Hamburg, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1215/15228517-2008-011DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2666233PMC
August 2008

Characteristics and outcome of pediatric patients enrolled in phase I oncology trials.

Oncologist 2008 Jun;13(6):679-89

Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, 10 Center Drive, Building 10-CRC, Room 1-3872, Bethesda, MD 20892, USA.

View Article

Download full-text PDF

Source
http://theoncologist.alphamedpress.org/cgi/doi/10.1634/theon
Publisher Site
http://dx.doi.org/10.1634/theoncologist.2008-0046DOI Listing
June 2008